Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $30.00
4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. Several other analysts have also recently weighed in on FDMT. HC Wainwright reaffirmed a “buy” rating and set a […]
4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. Several other analysts have also recently weighed in on FDMT. HC Wainwright reaffirmed a “buy” rating and set a […]
